SCHEMBL28050005

SCHEMBL28050005

C=CCOc1ccc2c(Cl)ncnc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.43
EGFR P00533 1/20 0.43
ERBB2 P04626 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
HPGD P15428 3/20 0.41
MAOA P21397 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
CA12 O43570 4/20 0.40
CA1 P00915 4/20 0.40
CA9 Q16790 4/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ADRA2A P08913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30640012 0.80 ENPP1 (0.55) FGFR1PDE4APDE4BPDE4CPDE4D
SCHEMBL8147583 0.80 ENPP1 (0.55) FGFR1PDE4APDE4BPDE4CPDE4D
SCHEMBL27969057 0.79 MAOA (0.47) FGFR1HPGDMAOAALDH1A1GAA
SCHEMBL1346309 0.78 PDE4A (0.44) FGFR1EGFRERBB2PDE4APDE4B
SCHEMBL3424568 0.78 PDE4A (0.44) FGFR1EGFRPDE4APDE4BPDE4C
SCHEMBL28049940 0.77 ENPP1 (0.50) FGFR1EGFRPDE4APDE4BPDE4C
SCHEMBL28050040 0.76 MAPT (0.45) FGFR1EGFRPDE4APDE4BPDE4C
SCHEMBL5044674 0.76 PDE4A (0.42) FGFR1EGFRPDE4APDE4BPDE4C
SCHEMBL4512570 0.76 KDR (0.57) FGFR1EGFRPDE4APDE4BPDE4C
SCHEMBL144584 0.76 EGFR (0.54) EGFRPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105294578-A Quinazoline derivative having targeted antitumor activity GUANGDONG WHOLEWIN TECHNOLOGY CO LTD 2016-02-03 CN disclosed